AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00557700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of inhaled tiotropium bromide
Description: Administration of inhaled tiotropium bromide
Study NCT00557700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of placebo
Description: Administration of placebo
Study NCT02894060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood tests
Description: Blood tests done by the nurse in the CRC (clinical research center). The quantity of blood taken wil be (3 5-mL tubes):~2 plain tubes and 1EDTA tube Arterial blood pressure will be measured at the CRC. Then, an X-ray of the profile of the abdomen will be taken without preparation to evaluate aortic calcification (in the radiology department of the Amiens hospital)
Study NCT04362761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination (FDC) tablet for oral administration.
Study NCT04362761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study NCT02922439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Intervention
Description: The intervention will focus on improving the health literacy of low literacy individuals by providing chronic disease self-management information tailored to cultural and linguistic characteristics of participants.
Study NCT02922439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: This intervention will provide information similar to that provided in the control condition, but will not utilize tailoring.
Study NCT00574405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])
Description: MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration.
Study NCT00574405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSII (Animas Corporation insulin pump, model IR 1200)
Description: CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
Study NCT02828839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Access needle
Description: The primary purpose of the single-use disposable access needle is to guide the use of a biopsy gun to obtain a tissue sample from the patient's prostate gland through a percutaneous puncture of the perineum. The primary purpose of the disposable needle guide is to stabilize the needle biopsy and better approximate the most direct path to the prostate.
Study NCT02553681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: roflufocon D contact lenses
Description: HPT treated rigid contact lenses
Study NCT02553681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RGP contact lenses made from roflufocon D
Study NCT00004123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride (DOX)
Description: Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.
Study NCT00004123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy
Study NCT02449356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prone position endotracheal tube(PPT)
Description: some special kind of endotracheal tube,including traditional air tube ,fixed device, fixed rope, and two through holes
Study NCT00978731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules:~* 5 days on, 2 days off~* 6 days on, 1 day off~* Continuous daily dosing~Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study
Study NCT02460640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tap block
Description: intravenous patient-controlled analgesia with morphine and tap block with subcostal and posterior approach with ropivacaine 0,5% 15ml+15ml
Study NCT02460640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous Patient controlled analgesia
Description: intravenous patient-controlled analgesia with morphine
Study NCT02460640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT02460640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT02258152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN120
Description: SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
Study NCT02258152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD
Study NCT02010424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: standard IVF protocol
Study NCT02010424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primo Vision embryo culture dish (CE labeled, Vitrolife)
Study NCT02616250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.33% gel (Br)
Study NCT02616250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD07805/47 (Br) placebo gel
Study NCT02616250 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CD07805/47 (Br) placebo gel
Study NCT02616250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 1% cream (IVM)
Study NCT02616250 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CD5024 (IVM) placebo cream
Study NCT00794872 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Study NCT00827372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib will be administered at a starting dose of 800 mg orally once each day.
Study NCT00004123 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Description: Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).
Study NCT00004123 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: 5 days a week for 4 weeks
Study NCT04635631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib
Description: Talazoparib will be administered orally on a continuous basis. Each cycle will consist of 28 days.
Study NCT03976921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Integration of CCTA with stress CTP when indicated
Description: When judged indicated, functional assessment with stress CTP perfusion will be performed on top of CCTA.
Study NCT03976921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care approach
Description: (a) functional non-invasive tests (stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET) as a gatekeeper for ICA; (b) direct referral to ICA.
Study NCT04651959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVICOD 200 MG Film Tablet
Description: AVICOD is containing 200 mg favipiravir manufactured by Pharma Plant,Turkey.
Study NCT04651959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVIGAN 200 MG Film Tablets
Description: AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
Study NCT00948805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: 3,6mg of goserelin acetate, 250mg of hCG, FSH variable dose according to the number of days required for appropriate ovarian stimulation
Study NCT00948805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 250mg of hCG, Zoladex, FSH variable dose according to the number of days required for appropriate ovarian stimulation
Study NCT01895894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 20\~30mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)
Study NCT03944122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: therapeutical ultrasound were applied to the patients
Study NCT02565381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal nicotine patch
Description: * ≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks~* \<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks
Study NCT02565381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Description: * ≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks~* \<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks
Study NCT02565381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person smoking cessation counseling
Description: - One-on-one 15-minute counseling sessions once per week for 8 weeks
Study NCT02565381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person smoking cessation counseling
Description: - One-on-one 15-minute counseling sessions once per week for 8 weeks
Study NCT02565381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingent financial rewards for smoking abstinence
Description: - Escalating-value financial rewards for smoking abstinence, verified by exhaled carbon monoxide \<8ppm
Study NCT02565381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages to support smoking abstinence
Description: - 1-5 text messages per day starting up to 2 weeks before the quit date and continuing until 6 weeks after the quit date, delivered by SmokefreeTXT
Study NCT03748940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC
Study NCT03748940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03748940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900021
Description: Administered SC
Study NCT01462903 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor infiltrating lymphocytes, IL-2
Description: Biological: Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells) by iv in 30 Minutes. Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
Study NCT01278459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 4 week treatment, 20mg/day taken orally in tablet form
Study NCT01008111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dermabond
Description: On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
Study NCT01008111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen Peroxide Oxygen producing gel
Description: On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
Study NCT01934153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Umeclidinium 18.5 mg
Description: Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.
Study NCT02692157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Neurokinin 1,3 antagonist
Study NCT02692157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NT-814 50 mg
Description: Neurokinin 1,3 antagonist 50 mg
Study NCT02692157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NT-814 100 mg
Description: Neurokinin 1,3 antagonist 100 mg
Study NCT02692157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NT-814 200 mg
Description: Neurokinin 1,3 antagonist 200 mg
Study NCT02321865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-02
Study NCT01931267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet Computer Motivated Instruction
Description: Using tablet computer to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects
Study NCT01931267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Systematic Instruction
Description: Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
Study NCT02492451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial Injury
Description: Endometrial injury in luteal phase of preceding cycle by pipelle canula
Study NCT02492451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone (Crinone® %8 vaginal progesterone gel)
Description: Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
Study NCT02649972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered at a dose of 60mg daily for 21 days on, then 7 days off, in a 28 day treatment cycle. Patients will have the option to discontinue treatment after 12 cycles and will be monitored for disease relapse for an additional 12 months. In the event that disease relapse occurs within the 12 month monitoring period, patients will restart treatment and continue on study. Upon restarting, the assessment schedule will restart at rechallenge cycle 1(RC-1) and all assessments will occur at the frequency and intervals. Cycle 1 Day 15 visits will not be required for patients that restart treatment after relapse. Participants will re-sign consent upon rechallenging.
Study NCT01395472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acute Physical Exercise
Description: Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.
Study NCT01395472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute Physical Exercise
Description: Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.
Study NCT01395472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching protocol
Description: TBI patients will be submitted to 30 minutes of stretching exercises composed of 15 exercises that prioritize back, legs and hip.
Study NCT03341624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cataract surgery cataract extraction and intraocular implantation
Study NCT03830294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: different temperature-controlled breast prostheses
Description: Two types of temperature-controlled breast prostheses were applied to patients in each group
Study NCT03830294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: different temperature-controlled breast prostheses
Description: Two types of temperature-controlled breast prostheses were applied to patients in each group
Study NCT03394014 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sciatic nerve block
Description: blocking sciatic nerve either at the subgluteal area or the popliteal region for effective anesthesia and analgesia during below knee amputation
Study NCT01437514 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preoperative short-course radiotherapy
Description: preoperative RT received a total dose of 25 Gy in five fractions during five consecutive days. The clinical target volume included the primary tumor and the mesentery with vascular supply containing the perirectal, presacral, and internal iliac nodes(up to the S1/S2 junction).The recommended upper border was at the level of the promontory. Radiation treatment was delivered with a three-portal technique.
Study NCT04402827 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Susceptibility to infection
Description: ACE2 and CD26 receptor study: After genomic DNA extraction and quantification using a NanoDrop-1000, 14 ACE2 SNPs (rs1978124, rs2048683, rs2074192, rs2106809, rs2285666, rs233575, rs4240157, rs4646142, rs4646155, rs4646156, rs4646188, rs4830542, rs6632677, and rs879922) will be studied. In addition, one CD26 (DPP4) SNP (rs7608798) will be analysed (qualitative measure).~SARS-CoV-2 CD4/CD8 T cell response: SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).~KIR characterization: Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed.
Study NCT01914432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH16410
Study NCT01914432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Study NCT01914432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT01914432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YH16410 placebo
Study NCT01914432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YH16410 placebo
Study NCT01914432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin placebo
Study NCT01914432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin placebo
Study NCT01914432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin placebo
Study NCT01914432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Telmisartan placebo
Study NCT01914432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan placebo
Study NCT01914432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan placebo
Study NCT04640311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be available as oral tablets.
Study NCT04206163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-TOC PET/CT
Description: Somatostatin receptor imaging
Study NCT04206163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Analysis of inflammatory biomarkers
Study NCT00856024 — intervention group
Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b
Description: PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
Study NCT03255226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
Study NCT03107442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 12-weeks aerobic exercise intervention based on the physical activity guidelines from the American College of Sports Medicine (≥150 min/week of moderate to vigorous \[40-85% of the individual's heart rate reserve\] exercise). Participants will perform the exercise on treadmills at the hospital. The volume and intensity of the exercise will progressively increase throughout the 12 weeks.
Study NCT04666012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCLD-CoV19
Description: Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.
Study NCT03890159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Assited Cognitive rehabilitation
Description: Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours. The total duration of intervention will be 1 month.